Jacobio Pharmaceuticals Group (JBPH.F) Stock Overview
An investment holding company, engages in the in-house discovery and development of oncology therapies in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
JBPH.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Jacobio Pharmaceuticals Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.87 |
| 52 Week High | HK$1.10 |
| 52 Week Low | HK$0.73 |
| Beta | 0.30 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -38.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| JBPH.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.3% | 0.8% |
| 1Y | n/a | 42.3% | 20.2% |
Return vs Industry: Insufficient data to determine how JBPH.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how JBPH.F performed against the US Market.
Price Volatility
| JBPH.F volatility | |
|---|---|
| JBPH.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: JBPH.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine JBPH.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 67 | Yinxiang Wang | www.jacobiopharma.com |
Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies in the People’s Republic of China. The company develops sitneprotafib (JAB-3312), an oral allosteric SHP2 inhibitor that is in a Phase III trial for non-small cell lung cancer (NSCLC); glecirasib (JAB-21822), a KRAS G12C allosteric inhibitor in Phase II trials for NSCLC, multi-tumor basket, and colorectal cancer; JAB-8263, a BET inhibitor that is in a Phase IIa trial for solid tumors and hematologic malignancies; JAB-BX102, a humanized monoclonal antibody against CD73, which is in a Phase I/IIa trial; JAB-2485, a highly selective Aurora Kinase A (AURKA) inhibitor that is in a Phase I/IIa trial for solid tumors; JAB-23E73, an oral small-molecule pan-KRAS inhibitor that is in a Phase I trial for KRAS-mutant PDAC, CRC, NSCLC, and solid tumors; and JAB-30355, a bioavailable small molecule p53 reactivator that is in a Phase I trial for the treatment of patients with locally advanced or metastatic solid tumors. It is also developing IND-enabling candidates, including JAB-BX467, JAB-BX600, and JAB-BX700 for solid tumor indications.
Jacobio Pharmaceuticals Group Co., Ltd. Fundamentals Summary
| JBPH.F fundamental statistics | |
|---|---|
| Market cap | US$443.10m |
| Earnings (TTM) | -US$21.60m |
| Revenue (TTM) | US$7.92m |
Is JBPH.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JBPH.F income statement (TTM) | |
|---|---|
| Revenue | CN¥53.53m |
| Cost of Revenue | CN¥593.00k |
| Gross Profit | CN¥52.93m |
| Other Expenses | CN¥198.91m |
| Earnings | -CN¥145.98m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.19 |
| Gross Margin | 98.89% |
| Net Profit Margin | -272.73% |
| Debt/Equity Ratio | 12.3% |
How did JBPH.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/17 13:38 |
| End of Day Share Price | 2026/03/20 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Jacobio Pharmaceuticals Group Co., Ltd. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yu Wu | CMB International Securities Limited |
| Linhai Zhao | Goldman Sachs |